Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency. (2021)
Attributed to:
Phase I/II trial of lentiviral vector mediated gene therapy for Adenosine Deaminase deficiency
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1056/nejmoa2027675
PubMed Identifier: 33974366
Publication URI: http://europepmc.org/abstract/MED/33974366
Type: Journal Article/Review
Volume: 384
Parent Publication: The New England journal of medicine
Issue: 21
ISSN: 0028-4793